GAL and hemophilia: Delivery of opt-NE-DNA carrying the hF.IX gene by employing a packaging vector like GAL-liposomes may hold promise for childhood hemophilia patients if factor levels >5% can be established to perturb severe symptoms and maintained with fewer administrations than regular prophylactic factor infusions.